Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vacuna Acuosa is an injectable allergen immunotherapy product developed by Alergo Pharma, an Argentinian company acquired by Stallergenes in 2014. It consists of unmodified allergen extracts diluted in an aqueous saline solution. The product is administered via subcutaneous injection to induce immunological tolerance and desensitize the immune system through repeated exposure to specific allergens. It is indicated for the treatment of allergic diseases, including allergic rhinitis, allergic asthma, and allergic conjunctivitis. As a traditional unmodified aqueous extract, it typically requires more frequent dosing compared to modified depot or polymerized formulations due to its immediate release profile and shorter stability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vacuna Acuosa.